Solventum : Presentation (image/SOLV 1Q25 Earnings Presentation 05082025 vF)

Published: 2025-05-08 17:08:39 ET SOLV

Published on 05/08/2025 at 17:08

Q1 FY25 earnings presentation

May 8, 2025

© Solventum 2025. All rights reserved.

Financial highlights

Net sales of $2.1B; +2.6%, organic sales growth +4.3%

Adjusted operating margins 19.7%

Adjusted EPS of $1.34

Increasing organic sales growth outlook by 50bps to +1.5% to +2.5%

Excludes additional SKU exit impact of 50bps

Maintaining adjusted EPS range of $5.45 to $5.65

Reflects positive underlying business performance, revised FX outlook, and other mitigations to absorb tariff headwinds in 2H 2025

Maintaining FCF range of $450M to $550M

Note: FY2025 guidance does not include the financial impact of announced P&F sale; will update following close

© Solventum 2025. All rights reserved. 3

1See non-GAAP financial measures and reconciliation schedules in the appendix of this document.

Q1 FY25 Financial summary

Dental Solutions

$328M

(2.1%) Reported

+0.4% Organic

Health Information Systems

$329M

+3.6% Reported

+3.9% Organic

Purification & Filtration

$242M

(0.9%) Reported

+2.2% Organic

Total Solventum1

+2.6% Y/Y Reported

+4.3% Y/Y Organic

MedSurg

$1,157M

+3.4% Reported

+6.0% Organic

GAAP

non-GAAP2

Operating margin

7.3%

19.7%

EPS

$0.78

$1.34

Cash from operations / Free cash flow2

$29

($80M)

1Corporate and unallocated includes sales from products supplied to 3M and other supply agreements related to legacy 3M non-health care business that were assumed by the company at spin-off.

2See non-GAAP financial measures and reconciliation schedules in the appendix of this document.

© Solventum 2025. All rights reserved. 4

MedSurg summary

Q1 financial results

Q1 FY25

Q1 FY24

Y/Y

Net sales

$1,157M

$1,119M

Reported +3.4%

Organic +6.0%

Organic growth driven by strong volume including timing benefits primarily in Infection Prevention and Surgical Solutions (IP&SS) for IV site management and hospital consumables

Advanced Wound Care (AWC) performance benefitting from adoption of single-use

negative pressure wound therapy (NPWT)

AWC

$448M | 39%

+1.5% Y/Y Rep

+2.8% Y/Y Org

$1,157M

+3.4% Y/Y Reported

+6.0% Y/Y Organic

IP&SS

$710M | 61%

+4.7% Y/Y Rep

+8.2% Y/Y Org

Tegaderm CHG Chlorhexidine

Gluconate IV Securement Dressings

The only transparent dressing cleared by the FDA to reduce catheter-related bloodstream infections (CRBSI) and vascular catheter colonization

5

Disclaimer

Solventum Corporation published this content on May 08, 2025, and is solely responsible for the information contained herein. Distributed via Public Technologies (PUBT), unedited and unaltered, on May 08, 2025 at 20:41 UTC.